Latest news with #RM206
New Straits Times
5 days ago
- Business
- New Straits Times
Y&G Corp units buy four Selangor land parcels worth RM395 mln
KUALA LUMPUR: Y&G Corporation Bhd's wholly-owned subsidiaries, Nusa Wibawa Sdn Bhd and Duta Asiana Sdn Bhd, have acquired four parcels of land worth RM395 million. On the breakdown, Y&G said Nusa Wibawa has acquired three parcels of leasehold land in Sepang, Selangor, with a combined area of approximately 38.45 hectares, from Nurani Saujana Sdn Bhd for RM206 million. It added that Duta Asiana Sdn Bhd has purchased a parcel of land measuring 148.52 hectares in Kuala Selangor, Selangor, from Asian Regal Holdings Sdn Bhd for RM189 million. "Y&G has also acquired one million ordinary shares in Konsep Wawasan Sdn Bhd, representing 100 per cent equity interest in the company, for a cash consideration of RM82 million," it said in a filing to Bursa Malaysia today.
Daily Express
30-06-2025
- Business
- Daily Express
Landowner reluctance slows road project, says Rina
Published on: Monday, June 30, 2025 Published on: Mon, Jun 30, 2025 By: Lagatah Toyos Text Size: Rina receiving a souvenir from a community representative. TAWAU: The reluctance of private landowners involved in the Jalan Utara development project to relinquish their land for development purposes has been identified as a key obstacle in expediting the completion of the project. Kukusan Assemblywoman Datuk Rina Jainal, said she was informed that some parties refused to release their land even though it was the government's responsibility to develop the area. 'However, this is currently being reviewed to speed up the development of Jalan Utara, which indeed has a significant impact on the residents of the Kukusan area,' she told the media on Thursday. According to her, the matter was raised during her meeting with Sabah Deputy Chief Minister, Datuk Ir Shahelmy Yahya, and Kalabakan Member of Parliament, Datuk Andi Muhammad Suryady Bandi, at his office recently to discuss the development of Jalan Utara, which is crucial for the Kukusan area. During the meeting, she also raised concerns regarding heavy vehicle transportation along Jalan Kalabakan, particularly involving the palm oil industry. Rina noted that while there is no immediate need for a dedicated route, industry players should act more responsibly in their use of other public roads. In the meantime, Rina urged civil servants and all relevant parties to act with integrity and professionalism to ensure that government development initiatives are not hindered by internal weaknesses. 'The public is watching our work…therefore, I hope all parties will uphold integrity and competitiveness in delivering the best services,' she added. For the record, the RM206 million Jalan Utara Baru road-widening project began in March 2023 and is expected to be completed within 36 months. * Follow us on our official WhatsApp channel and Telegram for breaking news alerts and key updates! * Do you have access to the Daily Express e-paper and online exclusive news? Check out subscription plans available. Stay up-to-date by following Daily Express's Telegram channel. Daily Express Malaysia
Free Malaysia Today
01-05-2025
- Health
- Free Malaysia Today
Ex-health minister urges govt to postpone mandatory drug price display
Former health minister Dr S Subramaniam said there was an urgent need for the ministry to go back to all stakeholders to better understand the actual situation on the ground and reconsider the move. PETALING JAYA : A former health minister has urged the government to postpone the implementation of mandatory drug price displays in private healthcare facilities, particularly general practitioner (GP) clinics, saying that the repercussions on the sector will be serious. This comes after the government yesterday said it is proceeding with making the policy mandatory starting today, despite the Malaysian Medical Association (MMA) claiming that it was not finalised yet. Dr S Subramaniam said there was an urgent need for the ministry to go back to all stakeholders to better understand the actual situation on the ground and reconsider the move. He said the findings from the cost-benefit analysis (CBA 2.0) conducted by the ministry in collaboration with the Malaysia Productivity Corporation have clearly outlined the long-term impact of the move, which has been opposed by the healthcare sector. 'The analysis clearly outlines the potential closure of up to 2,600 private clinics, with a projected RM206 billion net economic loss over 15 years and the risk of job losses ranging from 91,000 to 136,000. 'These are not just numbers, they represent the very foundation of our primary healthcare system. I urge the government to take these implications seriously and avoid policies that may destabilise the private health sector,' he said in a statement. Yesterday, it was announced that the enforcement of the new rule from May 1 would be carried out by the health ministry with the guidance and cooperation from the domestic trade and cost of living ministry. The two ministries reiterated that this initiative is in line with the government's agenda of ensuring price transparency for drugs. Subramaniam said the move is counterproductive especially to standalone GP clinics, as they operate on a hybrid model where drug sales help subsidise consultation fees, which are strictly regulated. He said mandating public price displays for medications in such a setting, without reforming consultation fee caps, is both impractical and potentially damaging. 'This policy risks undermining the sustainability of standalone clinics, many of which serve as the first point of contact for patients. 'Malaysia's private primary care pricing is among the most competitive globally and has not been a significant contributor to medical inflation. Disrupting this balance may lead to unintended cost burdens on the rakyat,' he added. Subramaniam, who is a former MIC president, urged the government to defer implementation until a comprehensive reform is undertaken after an in-depth discussion with all stakeholders. He said Malaysia's healthcare financing model requires a broad, structural review, adding that proposals like mandatory drug price displays should be part of a comprehensive reform agenda and not introduced in isolation.
